TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00245765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to Certolizumab Pegol
Study: NCT01619670

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apligraf
Description: non adhesive layer
Study: NCT04103528

Intervention type: OTHER
Group type: OTHER
Intervention: morning surgery
Description: 31 patients will be operated on between 8:00 and 12:00 in the morning.

Intervention type: OTHER
Group type: OTHER
Intervention: afternoon surgery
Description: 31 patients will be operated on between 14:00 and 18:00 in the afternoon.
Study: NCT02136927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1210
Study: NCT04814290

Intervention type: OTHER
Intervention: health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).
Description: health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).

Intervention type: OTHER
Intervention: health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).
Description: health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
Study: NCT02241499

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil.
Description: Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
Study: NCT02925546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
Study: NCT02136927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference1210
Study: NCT03449342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
Study: NCT01878708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: -dexamethasone 40mg daily for 4 days with every cycle.
Study: NCT02925546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
Study: NCT04686383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL056 mesylate
Description: Dosage form: 20 mg CAL056 mesylate/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL056 mesylate
Description: Dosage form: 20 mg CAL056 mesylate/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL056 mesylate
Description: Dosage form: 20 mg CAL056 mesylate/tablet
Study: NCT04441255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsule.
Study: NCT02925546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
Study: NCT01607697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Mindfulness Training
Study: NCT04213235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
Study: NCT04168593

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: 20 min of Acupuncture section follow by 10 min of cupping around the knee

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20 min of Acupuncture section follow by 10 min of cupping around the knee
Study: NCT03793517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY and ATG
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Study: NCT01986179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Interpretation
Description: Professional interpretation provided over the phone by a national network of certified medical interpreters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Interpretation
Description: Professional interpretation provided over video by a national network of certified medical interpreters
Study: NCT01376076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
Study: NCT03546114

Intervention type: OTHER
Intervention: Gender Questionnaire
Description: 13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
Study: NCT01238302

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional arthroscopic rotator cuff repair
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with PRP
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study: NCT01376076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone/Moxifloxacin
Description: Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone/Moxifloxacin
Description: Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
Study: NCT03759795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTr (Acceptance and Commitment Training)
Description: The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
Study: NCT02976909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Cisplatin+5fluorouracil
Description: Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
Study: NCT03861442

Intervention type: DEVICE
Intervention: Audio processor SONNET
Description: AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A

Intervention type: DEVICE
Intervention: SONNET 2: Configuration 1
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild

Intervention type: DEVICE
Intervention: SONNET 2: Configuration 2
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong

Intervention type: DEVICE
Intervention: SONNET 2: Configuration 3
Description: AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)

Intervention type: DEVICE
Intervention: SONNET 2: Configuration 4
Description: AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
Study: NCT02628561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Study: NCT03197376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: 10-Valent Pneumococcal Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: 10-Valent Pneumococcal Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: 10-Valent Pneumococcal Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
Study: NCT04202887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Fentanyl
Description: 10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Fentanyl
Description: 10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Ultrasonography
Description: The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Ultrasonography
Description: The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF.
Study: NCT03861442

Intervention type: DEVICE
Intervention: SONNET 2: OPUS 2 configuration
Description: AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A

Intervention type: DEVICE
Intervention: SONNET 2: SONNET configuration
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
Study: NCT04083287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalen brachial plexus block (Group I)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study: NCT02777294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational website
Description: Psycho-educational self-help website about rape-related PTSD
Study: NCT02999295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab (8 mg/kg) is administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab (8 mg/kg) is administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
Study: NCT01269138

Intervention type: DRUG
Intervention: plasma derived Factor VII
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis

Intervention type: DRUG
Intervention: recombinant FVIIa
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis

Intervention type: DRUG
Intervention: Fresh Frozen Plasma
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis

Intervention type: DRUG
Intervention: Activated Prothrombin Complex Concentrates
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis

Intervention type: DRUG
Intervention: Virus Inactivated plasma
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study: NCT04302233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New pharmaceutical support (NPS)
Description: The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
Study: NCT04358224

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dupilumab Prefilled Syringe
Description: open-label
Study: NCT02322970

Intervention type: DEVICE
Intervention: transcranial Doppler
Description: Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
Study: NCT03301298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo given as oral capsule.
Study: NCT02410239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Study: NCT02978833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Study: NCT03793764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: USG guided TAP block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: USG guided QL block
Study: NCT02978833

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT02937558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline